Purified Recombinant Human IL-5 (Accession # P05113)
This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Storage and Handling
The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Country of Origin
Next Day Ambient
Other Applications Reported In Literature ?
Neutralization: This antibody is useful for neutralization of Human IL-5 bioactivity. The antibody dose required to neutralize 50% (ND50) of the biological activity of Human IL-5 (at 1.25 ng/ml) is 0.01 - 0.03 µg/ml.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone 14611 recognizes an epitope on human IL-5. In direct ELISA, this antibody shows approximately 3% cross-reactivity with rmIL-5.
IL-5 is a 26 kD TH2 cytokine and a homodimeric glycoprotein that is part of the hematopoietic family. IL-5 stimulates B cell growth as well as increases Ig secretion. It is the main factor that promotes the terminal differentiation of eosinophil progenitors and enhances the effector capacity of mature eosinophils. IL-5 is a major regulator of eosinophil accumulation in tissues. In fact, in Hodgkin lymphoma, the characteristically observed eosinophilia is suspected to result from an increased production of IL-5. IL-5 may also be the cause of several allergic diseases including asthma, where it is thought that eosinophils have a significant role in the disease pathology. There are several mAbs currently in use that target IL-5 for the treatment of severe eosinophilic asthma.
References & Citations
1. Capron, M. et al. (1994) J Exp Med 179: 703
2. Graber, P. et al. (1993) Nature 363: 172
3. Inokuma, S. et al. (2005) Int Arch Allergy Immunol 1: 55
Products are for research use only. Not for use in diagnostic or therapeutic procedures.